Protalix BioTherapeutics price to free cash flow PLX

Market value divided by free cash flow over the last twelve months, since 2018.

Today, Oct 23, 2026: 26.8×
8-year median: 18.5×
Against its 8-year history: 83rd; percentile: 0 is its lowest day, 100 its highest
8-year range: 3.3× to 31.7×
Peer median: 12.8×

Protalix BioTherapeutics' price to free cash flow is 26.8× as of Oct 23, 2026.

That is above its 8-year median of 18.5×, higher than on 83% of days in the last 8 years.

Over that time it ranged from 3.3× in Dec 2018 to 31.7× in May 2025.

The median for 10 healthcare stocks of a similar size is 12.8×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	26.8×	12.3×	29.2×
2025	31.7×	21.8×	31.7×
2024	18.8×	14.4×	20.6×
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	5.6×	4.3×	6.2×
2018	3.3×	3.3×	5.1×

Against its peers

Companies in Healthcare nearest Protalix BioTherapeutics' size, closest first, today.

Company	Price to free cash flow
PLXProtalix BioTherapeutics	26.8×
PDEXPro DEX	29.5×
NATRNatures Sunshine Products	11.8×
ELMDElectromed	26.2×
UTMDUtah Medical Products	20.6×
INFUInfuSystem	12.1×
VMDViemed Healthcare	12.8×
EMBCEmbecta	2.3×
KEQUKewaunee Scientific	8.7×
ICCCImmucell	22.1×
ARVNArvinas	n/m
Peer median	12.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Protalix BioTherapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.